Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response

Title:Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response

Volume: 17 Issue: 9

Author(s): Inna I. Antoneeva, Tatyana V. Abakumova, Dinara R. Dolgova, Tatyana P. Gening*, Sabina S. Pirmamedova, Dinara F. Myasnikova and Snezhanna O. Gening

Affiliation:

• Department of Physiology and Pathophysiology of Ulyanovsk State University Ulyanovsk, 432017,Russian Federation

Keywords: Ovarian cancer, cytokines, gene polymorphism, serum, neoadjuvant, chemotherapy.

Abstract: Background: Polychemotherapy in ovarian cancer (OC) is the second major component of treatment. However, treatment with cytostatics is stopped in 25% of cases because of significant side effects. It is shown that concentration of certain cytokines and their balance is largely formed in accordance with a genetic polymorphism.

Objective: The objective of the study was to evaluate the cytokine status of blood serum of patients with ovarian cancer with different tumor response to neoadjuvant chemotherapy (NACT).

Method: Patients received 2 courses NACT according to the scheme AP. The levels of IL-1β and IL-1Ra, IL-10, TNF-α in blood serum were determined by solid phase ELISA. For molecular genetic studies we selected polymorphic variants in the promoters of the gene represented in dbS`NP NCBI and SNP500 Cancer databases.

Results: The sharply declined in patients with ovarian cancer compared with the normal, level of IL-1β correlates with increased levels of IL-1RA. It is found that 75% of patients who had progression of the disease after NACT bear CT genotype of gene IL-1β associated with a low expression of the cytokine, while the TT genotype, providing a high level of the expression of IL-1β gene had met only 25% among patients in this group. At the same time 70% of patients with a complete response are the carriers of the T allele, while a complete response was associated with a higher level of IL-1β than in the progression group.

Low secretion of TNF-α in all types of tumor response when testing TNF-α G-308A gene polymorphisms was associated with carriage of GA and AA genotypes, which are associated with low production of this cytokine.

Increased compared to the control IL-10 production in patients with ovarian cancer associated with genotype replacement at position 1082 G/A IL-10 gene, which occured in 10% of patients with a complete response and 25% of patients with tumor progression after NACT.

Conclusion: All the studied polymorphisms of IL-1β, IL-10 and TNF-α genes in patients with OC are associated with the level of these cytokines and tumor NACT response.

Cite this article as:

Antoneeva I. Inna, Abakumova V. Tatyana, Dolgova R. Dinara, Gening P. Tatyana*, Pirmamedova S. Sabina, Myasnikova F. Dinara and Gening O. Snezhanna, Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (9) . https://dx.doi.org/10.2174/1871520617666170103100350

DOI https://dx.doi.org/10.2174/1871520617666170103100350	Print ISSN 1871-5206
Publisher Name Bentham Science Publisher	Online ISSN 1875-5992